---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-068248"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:34:52.263394+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA reports 53% ORR in CPS≥20 subgroup from Phase2 HB-200 + pembro trial at ASCO

## Summary
- Among 35 evaluable first-line HPV16+ HNSCC patients, ORR 37%, CR 11%, DCR 69% per RECIST 1.1.
- In CPS≥20 subgroup (N=17, registrational target): ORR 53%, CR 18%, DCR 82%; PFS 16.3 mo, OS rate 88% at 9 mo.
- HB-200 + pembrolizumab well-tolerated; Grade≥3 TRAEs in 15%, no treatment-related deaths.
- Company plans to begin pivotal Phase 2/3 trial in Q4 2024 with FDA alignment on path to accelerated approval.
- Data presented as oral abstract at ASCO 2024; median follow-up for CPS≥20 subgroup was 8.4 months.

## SEC filing metadata
- accession: 0001104659-24-068248
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465924068248/0001104659-24-068248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465924068248/tm2416401d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-068248
- JSON: https://secwatch.observer/filing/0001104659-24-068248.json
- Plain text: https://secwatch.observer/filing/0001104659-24-068248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.